AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32060062 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32060165 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous or intramuscular thiamine (100 mg daily for a minimum of 3 days)
Number of subjects: 662
Study 32060165 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline assessments including physical examination, echocardiogram, and venous blood draw for thiamine biomarkers
Number of subjects: 662
Study 32060165 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessments including physical examinations and echocardiograms at specified intervals
Number of subjects: 662
Study 32060165 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression models to identify predictors of TRD
Number of subjects: 662
Study 32060165 — intervention group
Group type: COMPARATOR
Intervention: Comparison with a frequency-matched community-based cohort of mother-child pairs (n=265)
Number of subjects: 662
Study 32060403 — intervention group
Group type: EXPERIMENTAL
Intervention: Copanlisib
Number of subjects: 67
Study 32060608 — intervention group
Group type: EXPERIMENTAL
Intervention: Flagellin co-exposure with ovalbumin in a murine model of allergic asthma
Number of subjects: 0
Study 32060608 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of flagellin in house dust of asthma patients
Number of subjects: 0
Study 32060608 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominant-negative polymorphism in TLR5 (rs5744168)
Number of subjects: 0
Study 32060867 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg once daily
Number of subjects: 198
Study 32061408 — intervention group
Group type: EXPERIMENTAL
Intervention: High-increasing group (n=337)
Number of subjects: 2839
Study 32061408 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-increasing group (n=1178)
Number of subjects: 2839
Study 32061408 — intervention group
Group type: COMPARATOR
Intervention: Low-increasing group (n=1324)
Number of subjects: 2839
Study 32061453 — intervention group
Group type: EXPERIMENTAL
Intervention: Single ketamine infusion (0.5 mg/kg)
Number of subjects: 22
Study 32061453 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated ketamine infusions (0.5 mg/kg)
Number of subjects: 22
Study 32061453 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CBF in the fusiform
Number of subjects: 22
Study 32061453 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute changes in CBF in visual areas
Number of subjects: 22
Study 32061453 — intervention group
Group type: COMPARATOR
Intervention: Comparison with control group (N = 18, mean age = 36.11 ± 14.5 SD, 57% female)
Number of subjects: 22
Study 32061464 — intervention group
Group type: COMPARATOR
Intervention: 068 intervention arm
Number of subjects: 907
Study 32061464 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-risk group
Number of subjects: 907
Study 32061464 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-risk group
Number of subjects: 907
Study 32061464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever having had sex
Number of subjects: 907
Study 32061464 — intervention group
Group type: EXPERIMENTAL
Intervention: Borrowing money
Number of subjects: 907
Study 32061464 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 907
Study 32061464 — intervention group
Group type: EXPERIMENTAL
Intervention: Supporting more gender-equitable norms
Number of subjects: 907
Study 32061579 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of superficial dyspareunia
Number of subjects: 300
Study 32061579 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous difficulty conceiving
Number of subjects: 300
Study 32061579 — intervention group
Group type: EXPERIMENTAL
Intervention: Currently trying to conceive
Number of subjects: 300
Study 32061579 — intervention group
Group type: EXPERIMENTAL
Intervention: Nulliparity
Number of subjects: 300
Study 32061579 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 300
Study 32061579 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of deep dyspareunia
Number of subjects: 300
Study 32062041 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab therapy
Number of subjects: 620
Study 32062172 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined FFR and CFR measurements
Number of subjects: 455
Study 32062172 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment for lesions with FFR (≤0.8) and CFR (<2.0)
Number of subjects: 455
Study 32062681 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide autogel/depot (LAN) combined with peptide receptor radionuclide therapy (PRRT)
Number of subjects: 40
Study 32063120 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred revascularization with FFR >0.75
Number of subjects: 879
Study 32063340 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable model including European System for Cardiac Operative Risk Evaluation II and preoperative haemoglobin
Number of subjects: 537
Study 32063340 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable model including European System for Cardiac Operative Risk Evaluation II, preoperative haemoglobin, and pre-specified frailty characteristics (polypharmacy, gait speed, physical disability, preoperative health-related quality of life, and living alone)
Number of subjects: 537
Study 32063371 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidscreen questionnaire
Number of subjects: 15
Study 32063371 — intervention group
Group type: EXPERIMENTAL
Intervention: Wechsler Children's Intelligence Scale, NEuroPSYchological assessment, Rey figure test
Number of subjects: 15
Study 32063371 — intervention group
Group type: EXPERIMENTAL
Intervention: Krickenbeck score
Number of subjects: 15
Study 32063492 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide (160 mg/d) with ADT and RT (66 Gy)
Number of subjects: 38
Study 32063492 — intervention group
Group type: COMPARATOR
Intervention: Salvage RT and ADT
Number of subjects: 38
Study 32063605 — intervention group
Group type: EXPERIMENTAL
Intervention: TG01/GM-CSF with adjuvant gemcitabine (high antigen burden)
Number of subjects: 32
Study 32063605 — intervention group
Group type: EXPERIMENTAL
Intervention: TG01/GM-CSF with adjuvant gemcitabine (modified vaccination schedule with reduced antigen burden)
Number of subjects: 32
Study 32063845 — intervention group
Group type: EXPERIMENTAL
Intervention: Mephedrone plus alcohol (200 mg mephedrone + 0.8 g/kg alcohol)
Number of subjects: 11
Study 32063845 — intervention group
Group type: COMPARATOR
Intervention: Mephedrone alone (200 mg mephedrone + placebo alcohol)
Number of subjects: 11
Study 32063845 — intervention group
Group type: COMPARATOR
Intervention: Alcohol alone (placebo mephedrone + 0.8 g/kg ethanol)
Number of subjects: 11
Study 32063845 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo mephedrone + placebo alcohol)
Number of subjects: 11
Study 32064291 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular shoulder exercise (SINEX)
Number of subjects: 56
Study 32064291 — intervention group
Group type: COMPARATOR
Intervention: Standard care exercise (HOMEX)
Number of subjects: 56
Study 32064663 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital treatment augmentation study
Number of subjects: 187
Study 32064766 — intervention group
Group type: EXPERIMENTAL
Intervention: Bottom-up costing method
Number of subjects: 10
Study 32064766 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-down costing method
Number of subjects: 10
Study 32064766 — intervention group
Group type: EXPERIMENTAL
Intervention: ART drug costs
Number of subjects: 10
Study 32064766 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost variability
Number of subjects: 10
Study 32064766 — intervention group
Group type: EXPERIMENTAL
Intervention: Missing capacity costs
Number of subjects: 10
Study 32064766 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall conclusion
Number of subjects: 10
Study 32065043 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate (HR) during exercise as measured by sports watch data
Number of subjects: 177
Study 32065330 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-4178 (adafosbuvir 800 mg QD, odalasvir 25 mg QD, simeprevir 75 mg QD) for 8 weeks (Cohort 1) or 12 weeks (Cohort 2)
Number of subjects: 33
Study 32065330 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-4178 (adafosbuvir 800 mg QD, odalasvir 25 mg QD, simeprevir 75 mg QD)
Number of subjects: 33
Study 32065359 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5 mg/ezetimibe 10 mg once daily
Number of subjects: 136
Study 32065359 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg once daily
Number of subjects: 136
Study 32065586 — intervention group
Group type: EXPERIMENTAL
Intervention: ARC-HBR criteria
Number of subjects: 12121
Study 32065631 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate/emtricitabine 300/200 mg daily for 14 days
Number of subjects: 15
Study 32065631 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (historical controls)
Number of subjects: 15
Study 32065631 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (intracellular measurements)
Number of subjects: 15
Study 32066275 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated adaptive atlas algorithm for segmenting the left ventricle on CAC-CT, extracting 107 radiomics features.
Number of subjects: 1982
Study 32066275 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression models using different feature selection methods based on CAC-CT radiomics, sex, height, and body surface area.
Number of subjects: 1982
Study 32066475 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-structured single interviews with former PMD patients
Number of subjects: 24
Study 32066475 — intervention group
Group type: EXPERIMENTAL
Intervention: Interprofessional focus groups with health and social care professionals
Number of subjects: 24
Study 32066540 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg once daily, taken orally, until progression or unacceptable toxicity.
Number of subjects: 34
Study 32066561 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading Centres (RCs)
Number of subjects: 205
Study 32066561 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinicians
Number of subjects: 205
Study 32066588 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (vCT and rCT)
Number of subjects: 555
Study 32066588 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (vCT and rectally untested)
Number of subjects: 555
Study 32066588 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (single vCT)
Number of subjects: 555
Study 32066588 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D (single rCT)
Number of subjects: 555
Study 32066601 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional decline during hospitalization
Number of subjects: 3555
Study 32066601 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional decline group
Number of subjects: 3555
Study 32066601 — intervention group
Group type: COMPARATOR
Intervention: No functional decline group
Number of subjects: 3555
Study 32066601 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent risk factors for functional decline
Number of subjects: 3555
Study 32066622 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumen-apposing metal stent placement
Number of subjects: 0
Study 32066978 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel
Number of subjects: 0
Study 32067048 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-Hib and 13-valent pneumococcal conjugate vaccine (PCV13) concurrently, followed by 23-valent pneumococcal polysaccharide vaccine (PPV23) 2 months later.
Number of subjects: 74
Study 32067048 — intervention group
Group type: COMPARATOR
Intervention: Control group (immunocompetent children)
Number of subjects: 74
Study 32067158 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Number of subjects: 0
Study 32067594 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-contrast computed tomography-based IVT
Number of subjects: 229
Study 32067594 — intervention group
Group type: COMPARATOR
Intervention: Control (non-thrombolyzed)
Number of subjects: 229
Study 32067679 — intervention group
Group type: EXPERIMENTAL
Intervention: PIK3CA-mutated HR+/Her2- mBC
Number of subjects: 649
Study 32067679 — intervention group
Group type: EXPERIMENTAL
Intervention: PIK3CA-mutated TNBC
Number of subjects: 649
Study 32067679 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual PIK3CA mutations in plasma after chemotherapy
Number of subjects: 649
Study 32067679 — intervention group
Group type: EXPERIMENTAL
Intervention: PIK3CA mutation distribution in mTNBC
Number of subjects: 649
Study 32067683 — intervention group
Group type: EXPERIMENTAL
Intervention: pertuzumab + trastuzumab (HER2 alteration)
Number of subjects: 19
Study 32067683 — intervention group
Group type: EXPERIMENTAL
Intervention: pertuzumab + trastuzumab (HER2 mutation)
Number of subjects: 19
Study 32067683 — intervention group
Group type: EXPERIMENTAL
Intervention: vismodegib (PTCH-1 mutation)
Number of subjects: 19
Study 32067683 — intervention group
Group type: EXPERIMENTAL
Intervention: vemurafenib (BRAF mutation)
Number of subjects: 19
Study 32067683 — intervention group
Group type: EXPERIMENTAL
Intervention: atezolizumab (high TMB)
Number of subjects: 19
Study 32067683 — intervention group
Group type: EXPERIMENTAL
Intervention: chemotherapy-free regimens matched to specific molecular alterations
Number of subjects: 19
Study 32067695 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal treatment of underlying conditions
Number of subjects: 0
Study 32068113 — intervention group
Group type: EXPERIMENTAL
Intervention: Early localization of lesions in patients with biochemical recurrence of prostate cancer
Number of subjects: 0
Study 32068685 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower sedentary time
Number of subjects: 182
Study 32068685 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater light physical activity
Number of subjects: 182
Study 32068685 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater moderate-vigorous physical activity
Number of subjects: 182
Study 32068685 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater vigorous physical activity
Number of subjects: 182
Study 32068685 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater total physical activity
Number of subjects: 182
Study 32068685 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical activity
Number of subjects: 182
Study 32068884 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted arterial oxygen tension of 8 kPa
Number of subjects: 2928
Study 32068884 — intervention group
Group type: COMPARATOR
Intervention: Targeted arterial oxygen tension of 12 kPa
Number of subjects: 2928
Study 32069106 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-stent strategy for LM bifurcation lesions
Number of subjects: 2648
Study 32069106 — intervention group
Group type: COMPARATOR
Intervention: 1-stent strategy for non-LM bifurcation lesions
Number of subjects: 2648
Study 32069759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 1 (19.2% of participants) - users with combined potential psychological and social issues
Number of subjects: 2319
Study 32069759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 2 (32.3% of participants) - users with potential social but no psychological issues
Number of subjects: 2319
Study 32069759 — intervention group
Group type: COMPARATOR
Intervention: Cluster 3 (45.6% of participants) - users with no potential issues of either a social or psychological nature
Number of subjects: 2319
Study 32070310 — intervention group
Group type: EXPERIMENTAL
Intervention: C. perfringens colonization
Number of subjects: 333
Study 32070310 — intervention group
Group type: COMPARATOR
Intervention: Maternal milk feeds
Number of subjects: 333
Study 32070310 — intervention group
Group type: COMPARATOR
Intervention: CPAP oxygen treatment
Number of subjects: 333
Study 32070310 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic treatment
Number of subjects: 333
Study 32070310 — intervention group
Group type: COMPARATOR
Intervention: Bifidobacterium infantis
Number of subjects: 333
Study 32070310 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxin gene screening
Number of subjects: 333
Study 32070711 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic gastroplication
Number of subjects: 10
Study 32071042 — intervention group
Group type: EXPERIMENTAL
Intervention: KBP-7072 (oral and intravenous formulations)
Number of subjects: 0
Study 32071055 — intervention group
Group type: EXPERIMENTAL
Intervention: LPV/r-4:4 with rifampin
Number of subjects: 87
Study 32071055 — intervention group
Group type: EXPERIMENTAL
Intervention: LPV/r-4:1 (1 month after treatment completion)
Number of subjects: 87
Study 32071135 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated oxygen titration to maintain stable oxygenation
Number of subjects: 60
Study 32071135 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated oxygen titration to correct hypoxemia
Number of subjects: 60
Study 32071135 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen delivery through a gas mask
Number of subjects: 60
Study 32071135 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized oxygen targets
Number of subjects: 60
Study 32071189 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary mobile unit (MMU) team intervention delivering urgent care at the bedside.
Number of subjects: 0
Study 32071189 — intervention group
Group type: COMPARATOR
Intervention: Usual care (ED referral in every case of urgency).
Number of subjects: 0
Study 32071189 — intervention group
Group type: EXPERIMENTAL
Intervention: MMU team intervention.
Number of subjects: 0
Study 32071418 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib therapy in acute srGVHD
Number of subjects: 75
Study 32071418 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib therapy in chronic srGVHD
Number of subjects: 75
Study 32071418 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib therapy in both acute and chronic srGVHD
Number of subjects: 75
Study 32071614 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported self-management (SSM) intervention for 2 months, consisting of a workbook and supportive coaching.
Number of subjects: 376
Study 32071614 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual (control) for 4 months, followed by SSM intervention.
Number of subjects: 376
Study 32071614 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported self-management (SSM) intervention
Number of subjects: 376
Study 32071868 — intervention group
Group type: EXPERIMENTAL
Intervention: Eunkyosan
Number of subjects: 375
Study 32071868 — intervention group
Group type: EXPERIMENTAL
Intervention: Samsoeum
Number of subjects: 375
Study 32071868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study 32071868 — intervention group
Group type: EXPERIMENTAL
Intervention: Eunkyosan or Samsoeum or Placebo
Number of subjects: 375
Study 32072073 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge translation (KT) intervention in 19 homes
Number of subjects: 5478
Study 32072073 — intervention group
Group type: COMPARATOR
Intervention: Control group in 21 homes
Number of subjects: 5478
Study 32072073 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero inflated negative binomial method (primary approach)
Number of subjects: 5478
Study 32072073 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized estimating equation (GEE) method
Number of subjects: 5478
Study 32072073 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-effects method
Number of subjects: 5478
Study 32072130 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn-Soy Blend Plus (CSB+) with fortified vegetable oil
Number of subjects: 6112
Study 32072130 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn-Soy-Whey Blend (CSWB) with oil
Number of subjects: 6112
Study 32072130 — intervention group
Group type: EXPERIMENTAL
Intervention: SuperCereal Plus (SC+)
Number of subjects: 6112
Study 32072130 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-use supplementary food (RUSF)
Number of subjects: 6112
Study 32072130 — intervention group
Group type: COMPARATOR
Intervention: Control group (reference food)
Number of subjects: 6112
Study 32072131 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein isolate (WPI)
Number of subjects: 30
Study 32072131 — intervention group
Group type: EXPERIMENTAL
Intervention: Pea protein isolate (PPI)
Number of subjects: 30
Study 32072161 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fish oil (FO) 1 g/kg/d
Number of subjects: 14
Study 32072570 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and diet intervention for 6 weeks
Number of subjects: 16
Study 32073546 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental assessments using instruments commonly used for early intervention screening in the community.
Number of subjects: 29
Study 32073546 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental assessments focusing on motor, cognitive, and language development.
Number of subjects: 29
Study 32073546 — intervention group
Group type: COMPARATOR
Intervention: Early intervention services.
Number of subjects: 29
Study 32073546 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimethod approach to repeated assessments for young children with NPC1.
Number of subjects: 29
Study 32073546 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation for early intervention services and consideration of investigational therapeutic interventions.
Number of subjects: 29
Study 32073681 — intervention group
Group type: COMPARATOR
Intervention: GBA PD
Number of subjects: 599
Study 32073681 — intervention group
Group type: COMPARATOR
Intervention: LRRK2 PD
Number of subjects: 599
Study 32073681 — intervention group
Group type: COMPARATOR
Intervention: GBA PD and LRRK2 PD
Number of subjects: 599
Study 32073954 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance olaparib
Number of subjects: 2206
Study 32074275 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA) at 75 mg/m2 subcutaneously or IV once daily on days 1 to 5 followed by HiDAC (3000 mg/m2) and mitoxantrone (30 mg/m2) once each on days 6 and 10.
Number of subjects: 46
Study 32074275 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA) at 50 mg/m2 (dose-limiting toxicities occurred).
Number of subjects: 46
Study 32074275 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA) at 37.5 mg/m2 (not specifically reported).
Number of subjects: 46
Study 32074275 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with favorable European Leukemia Network risk.
Number of subjects: 46